Cypre Status
The company raised $150,000 of convertible debt funding from undisclosed investors on August 24, 2018. Earlier, the company raised an undisclosed amount of venture funding from Hemi Ventures on January 1, 2017.
Developer of a tumor microenvironment system intended to be used for the transformative 3D cellular research and clinical testing of cancer patients. The company's tumor microenvironment system consists of extracellular matrix remodeling, immune infiltration and other processes that influence tumor progression, enabling medical institutions with better and advanced drugs, opening the door for a new generation of therapeutics and patient success.
Year Founded
2016
General Information
-
Website
-
Business Status
Generating Revenue
-
Ownership Status
Privately Held (backing)
-
Financing Status
Venture Capital-Backed
Cypre News and Updates
Racecard | 18:58 Des Cypres Claiming Stakes | Fontainebleau (FR) | Sky Sports Horse Racing
Sky Sports | April 27, 2022
Château Climens 'Cyprès de Climens' Barsac 2016, Bordeaux, France
VinePair | March 16, 2022
More gas pains for T&T
Trinidad Guardian | February 9, 2022
Young: Renewables on horizon but oil, gas here for medium term
TT Newsday | September 16, 2021
Tofino Hatchery receives $10K donation – Tofino-Ucluelet Westerly News - Tofino
Tofino-Ucluelet Westerly News | June 15, 2021
Cypre's Verticals
Cypre Primary Industry Sector / Group / Code
Cypre's Trends
Cypre Metrics
Majestic Referring Domains
Headquarters
-
HQ Address Line 1953 Indiana Street
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ Post Code94107
-
HQ CountryUnited States
Cypre's Keywords
mood_badFeed is empty.
Add a review